Sun Pharma Licenses Lerodalcibep Globally Excluding US and China from LIB Therapeutics
Sun Pharmaceutical Industries Ltd 路 Press Release 路 28 Sept 2026, 1:50 pm
Sun Pharma Licenses Lerodalcibep Globally Excluding US and China from LIB Therapeutics Sun Pharma secured exclusive worldwide commercialization and manufacturing rights, excluding the US and China, for LIB Therapeutics' lerodalcibep (Lyrokaul in the EU), an EMA-approved once-monthly PCSK9 inhibitor for hypercholesterolaemia. Under the agreement, LIB receives upfront and milestone payments plus net sales royalties. The deal expands Sun Pharma鈥檚 innovative portfolio into an ex-US/China PCSK9 market valued at US$3.7B as of MAT Q2'26 (Europe accounting for US$2.9B), growing at a 38% CAGR, while the global market approaches US$7B in 2026.
Original exchange filing (PDF)
More announcements from Sun Pharmaceutical Industries Ltd
- Intimation of Schedule of Analyst/Institutional Investor Meeting 路 05 Nov 2026
- Q2FY27 Earnings Call Transcript 路 05 Nov 2026
- Clarification regarding news report relating to the Company''s Assam facility 路 03 Nov 2026
- The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on November 2, 2026, with reference to news appeared in https://www.thehindu.com/ dated October 30, 2026 quoting .... 路 02 Nov 2026
- Completion and results of postal ballot dated 01 October 2026 路 01 Nov 2026
- Q2FY27- Investor Call Audio Recording 路 31 Oct 2026
- Board Meeting Outcome - Conclusion 路 30 Oct 2026
- Unaudited Financial Results for the quarter and half year ended 30 September 2026 路 30 Oct 2026
